Glucose tolerance in Canadian and French cystic fibrosis adult patients

Abstract Cystic fibrosis (CF)-related diabetes is associated with increased mortality. We analysed the clinical and glycemic profiles of two cohorts of patients treated according to the same guidelines in France and Canada. To investigate incidence differences in phenotypic and glucose abnormalities...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Quitterie Reynaud, Valérie Boudreau, Sandrine Touzet, Katherine Desjardins, Stéphanie Poupon Bourdy, Emilie Blond, Yves Berthiaume, Rémi Rabasa-Lhoret, Isabelle Durieu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ea68f3c1206447ae808634324d5b1e4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea68f3c1206447ae808634324d5b1e4c
record_format	dspace
spelling	oai:doaj.org-article:ea68f3c1206447ae808634324d5b1e4c2021-12-02T16:07:52ZGlucose tolerance in Canadian and French cystic fibrosis adult patients10.1038/s41598-019-40592-92045-2322https://doaj.org/article/ea68f3c1206447ae808634324d5b1e4c2019-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-019-40592-9https://doaj.org/toc/2045-2322Abstract Cystic fibrosis (CF)-related diabetes is associated with increased mortality. We analysed the clinical and glycemic profiles of two cohorts of patients treated according to the same guidelines in France and Canada. To investigate incidence differences in phenotypic and glucose abnormalities and to explore the evolution over a 4-year follow-up period, two cohorts of 224 Canadian and 147 French adult CF patients (≥18 years) without treated CF-related diabetes (CFRD) were followed over a 4 year period. In each of these groups, we investigated the longitudinal relationship between glucose tolerance and pulmonary function. An annual 2-hour oral glucose tolerance test was performed: fasting blood glucose (G0) and 2-h blood glucose (G2) were measured. Patients were classified at inclusion according to their glucose tolerance status: Normal glucose tolerant, abnormal glucose tolerant or de novo CFRD. Age, sex ratio and proportion of F508del homozygous patients were not statistically different between both cohorts. Canadian patients had better pulmonary function (median %FEV1 (IQR): 71.0 (55.0–82.0) vs. 64.0 (40.0–78.0), p < 0.001) and greater body mass index (BMI; median BMI in kg/m2) (IQR) 21.1 (19.5–22.8) vs. 19.9 (18.4–21.4), p < 0.001). Glucose values: G0 (5.4 (5.0–5.9) vs. 4.8 (4.5–5.1) mmol/L, p < 0.001) and G2 (7.6 (5.8–9.7) vs. 6.5 (5.2–8.5) mmol/L, p = 0.001) were higher in the Canadian cohort translating into a higher incidence of de novo CFRD diagnosis (19.2 vs. 9.8%, p = 0.003). Decline in FEV1 over time was not different between patients according to glucose tolerance groups. Despite higher glucose levels and incidence of de novo CFRD, Canadian CF patients have a better lung function and a higher BMI than French patients. In spite of these differences between the cohorts, the decline in FEV1 in patients with abnormal glucose tolerance is similar between these groups.Quitterie ReynaudValérie BoudreauSandrine TouzetKatherine DesjardinsStéphanie Poupon BourdyEmilie BlondYves BerthiaumeRémi Rabasa-LhoretIsabelle DurieuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 9, Iss 1, Pp 1-8 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Quitterie Reynaud Valérie Boudreau Sandrine Touzet Katherine Desjardins Stéphanie Poupon Bourdy Emilie Blond Yves Berthiaume Rémi Rabasa-Lhoret Isabelle Durieu Glucose tolerance in Canadian and French cystic fibrosis adult patients
description	Abstract Cystic fibrosis (CF)-related diabetes is associated with increased mortality. We analysed the clinical and glycemic profiles of two cohorts of patients treated according to the same guidelines in France and Canada. To investigate incidence differences in phenotypic and glucose abnormalities and to explore the evolution over a 4-year follow-up period, two cohorts of 224 Canadian and 147 French adult CF patients (≥18 years) without treated CF-related diabetes (CFRD) were followed over a 4 year period. In each of these groups, we investigated the longitudinal relationship between glucose tolerance and pulmonary function. An annual 2-hour oral glucose tolerance test was performed: fasting blood glucose (G0) and 2-h blood glucose (G2) were measured. Patients were classified at inclusion according to their glucose tolerance status: Normal glucose tolerant, abnormal glucose tolerant or de novo CFRD. Age, sex ratio and proportion of F508del homozygous patients were not statistically different between both cohorts. Canadian patients had better pulmonary function (median %FEV1 (IQR): 71.0 (55.0–82.0) vs. 64.0 (40.0–78.0), p < 0.001) and greater body mass index (BMI; median BMI in kg/m2) (IQR) 21.1 (19.5–22.8) vs. 19.9 (18.4–21.4), p < 0.001). Glucose values: G0 (5.4 (5.0–5.9) vs. 4.8 (4.5–5.1) mmol/L, p < 0.001) and G2 (7.6 (5.8–9.7) vs. 6.5 (5.2–8.5) mmol/L, p = 0.001) were higher in the Canadian cohort translating into a higher incidence of de novo CFRD diagnosis (19.2 vs. 9.8%, p = 0.003). Decline in FEV1 over time was not different between patients according to glucose tolerance groups. Despite higher glucose levels and incidence of de novo CFRD, Canadian CF patients have a better lung function and a higher BMI than French patients. In spite of these differences between the cohorts, the decline in FEV1 in patients with abnormal glucose tolerance is similar between these groups.
format	article
author	Quitterie Reynaud Valérie Boudreau Sandrine Touzet Katherine Desjardins Stéphanie Poupon Bourdy Emilie Blond Yves Berthiaume Rémi Rabasa-Lhoret Isabelle Durieu
author_facet	Quitterie Reynaud Valérie Boudreau Sandrine Touzet Katherine Desjardins Stéphanie Poupon Bourdy Emilie Blond Yves Berthiaume Rémi Rabasa-Lhoret Isabelle Durieu
author_sort	Quitterie Reynaud
title	Glucose tolerance in Canadian and French cystic fibrosis adult patients
title_short	Glucose tolerance in Canadian and French cystic fibrosis adult patients
title_full	Glucose tolerance in Canadian and French cystic fibrosis adult patients
title_fullStr	Glucose tolerance in Canadian and French cystic fibrosis adult patients
title_full_unstemmed	Glucose tolerance in Canadian and French cystic fibrosis adult patients
title_sort	glucose tolerance in canadian and french cystic fibrosis adult patients
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/ea68f3c1206447ae808634324d5b1e4c
work_keys_str_mv	AT quitteriereynaud glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT valerieboudreau glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT sandrinetouzet glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT katherinedesjardins glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT stephaniepouponbourdy glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT emilieblond glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT yvesberthiaume glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT remirabasalhoret glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients AT isabelledurieu glucosetoleranceincanadianandfrenchcysticfibrosisadultpatients
_version_	1718384690508857344

Glucose tolerance in Canadian and French cystic fibrosis adult patients

Ejemplares similares